{"nctId":"NCT01448707","briefTitle":"A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment","startDateStruct":{"date":"2012-03-15","type":"ACTUAL"},"conditions":["Human Immunodeficiency Virus (HIV) Infections","Acquired Immunodeficiency Syndrome (AIDS) Virus"],"count":274,"armGroups":[{"label":"Darunavir monotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Darunavir","Drug: Ritonavir"]},{"label":"Triple therapy containing darunavir","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Darunavir","Drug: Ritonavir"]}],"interventions":[{"name":"Darunavir","otherNames":[]},{"name":"Ritonavir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HIV-1 infection\n* receiving HAART for at least 48 weeks\n* Have at least 2 documented plasma HIV-1 RNA \\<50 copies/mL, and no HIV-1 RNA \\>=50 copies/mL in the 48 weeks prior to the screening\n* Be taking the same antiretroviral (ARV) combination for at least 8 weeks before screening\n* Have the preference, together with the physician, to change the current HAART regimen for reasons of simplification and/or toxicity\n\nExclusion Criteria:\n\n* Has a history of virologic failure defined as 2 consecutive plasma HIV-1 RNA \\>500 copies/mL while on previous or current antiretroviral therapy\n* Has a history of any primary PI mutations\n* Has clinical or laboratory evidence of significantly decreased hepatic function or decompensation, irrespective of liver enzyme levels (liver insufficiency)\n* Is diagnosed with acute viral hepatitis at screening or before Baseline 1\n* Is co-infected with hepatitis B","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Virologic Response (Food Drug and Administration [FDA] Snapshot, Switch = Failure)","description":"The percentage of participants who have plasma human immunodeficiency virus type-1 (HIV-1) ribonucleic acid (RNA) levels \\<50 copies/milliliters \\[mL\\] after 48 weeks of follow-up. Switch = Failure is defined as switch in background nucleoside/nucleotide reverse transcriptase inhibitors (N\\[t\\]RTIs) not permitted by the trial protocol or plasma HIV-1 RNA assessment closest to target date of the analysis time point window (44-52 weeks) and next/confirmation of Plasma HIV-1 RNA in the analysis time point window above the threshold or discontinuation for any other reason.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.0","spread":null},{"groupId":"OG001","value":"95.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (Food Drug and Administration [FDA] Snapshot, Switch = Failure)","description":"The percentage of participants who have plasma human immunodeficiency virus type-1 (HIV-1) ribonucleic acid (RNA) levels \\<50 copies/milliliters \\[mL\\] after 96 weeks of follow-up after switching to DRV/ritonavir(rtv) monotherapy versus triple therapy containing DRV/rtv. Switch = Failure is defined as switch in background nucleoside/nucleotide reverse transcriptase inhibitors (N\\[t\\]RTIs) not permitted by the trial protocol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.2","spread":null},{"groupId":"OG001","value":"85.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response (FDA Snapshot, Switch Included)","description":"The percentage of participants who have plasma human immunodeficiency virus type-1 (HIV-1) ribonucleic acid (RNA) levels \\<50 copies/milliliters \\[mL\\] after 48 and 96 weeks of follow-up after switching to DRV/ritonavir(rtv) monotherapy versus triple therapy containing DRV/rtv. Switch included is defined as all participants who discontinued randomized medication were followed up on their subsequent treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.0","spread":null},{"groupId":"OG001","value":"96.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.3","spread":null},{"groupId":"OG001","value":"89.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Global Neurocognitive Performance z-Score","description":"Change in neurocognitive function of DRV/rtv monotherapy versus triple therapy containing DRV/rtv over 48 and 96 weeks. Neurocognitive function will be measured by Hopkins Verbal Learning Test (verbal learning and memory), Colour Trail Test (psychomotor speed and cognitive flexibility) and Grooved Pegboard Test (psychomotor speed and fine motor function). Higher values for change in z-score represent an improvement in Neurocognitive Performance (NP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.048"},{"groupId":"OG001","value":"0.42","spread":"0.057"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.060"},{"groupId":"OG001","value":"0.57","spread":"0.057"}]}]}]},{"type":"SECONDARY","title":"Time to Loss of Virologic Response","description":"Time (in days) it takes to show loss of response per time to loss of virologic response (TLOVR) algorithm: confirmed HIV-1 RNA \\>= 50 copies/mL or premature discontinuation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"19.92"},{"groupId":"OG001","value":"NA","spread":"18.88"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Treatment-Emergent Phenotypic Drug Resistance","description":"The loss of treatment options of DRV/rtv monotherapy versus triple therapy containing DRV/rtv at Weeks 48 and 96, as defined by treatment-emergent phenotypic drug resistance. Drug resistance is classified as: 1) Confirmed HIV RNA \\>= 400 copies/mL, 2) Post-baseline phenotypic data and 3) Phenotypic resistance to any of the drug classes (NRTI, NNRTI, or PI).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Resistance Mutations With Confirmed Virologic Failure Who Have HIV RNA >400 Copies/mL and Genotype Resistance Results","description":"The viral genotype of participants treated with DRV/rtv monotherapy versus triple therapy containing DRV/rtv over 48 and 96 weeks. Genotypic resistance (number of resistance mutations) at any time point when a participant had a confirmed plasma VL \\>400 copies/mL after randomization was performed per treatment group for the ITT population. Results were summarized based on individual treatment received: Darunavir resistance mutations, non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations, nucleoside reverse transcriptase inhibitor (NRTI) mutations, protease inhibitor (PI) resistance mutations, PR mutations, RT mutations, extended NNRTI mutations, primary PI mutations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":137},"commonTop":["Diarrhoea","Nasopharyngitis","Headache","Cough","Fatigue"]}}}